Dual PARP/Tankyrase Inhibition Enhances Antitumor Efficacy in PTEN-Deficient Endometrial Cancer - PubMed
3 hours ago
- #PTEN-deficient
- #PARP inhibitor
- #endometrial cancer
- Dual PARP/tankyrase inhibitor JPI-547 shows potent antitumor activity in PTEN-deficient endometrial cancer.
- Combined targeting of PARP and tankyrase induces synergistic cytotoxicity and increased DNA damage in PTEN-deficient cells.
- Inhibition modulates non-homologous end joining and attenuates Wnt/β-catenin signaling, enhancing vulnerability to treatment.
- PTEN loss enhances sensitivity to dual inhibition, supporting it as a potential therapeutic strategy for endometrial cancer.